Once-weekly treatment for adults with type 2 diabetes comes in a pen with a no-see, no-handle needle INDIANAPOLIS, Nov. 10, 2014 /PRNewswire/ -- The newest GLP-1 receptor agonist treatment option to ...

Trulicity, a weekly glucagon-like peptide-1 (GLP-1) receptor agonist, is indicated for adults with type 2 diabetes as an adjunct to diet and exercise The single-dose pen does not require mixing nor ...

The Food and Drug Administration (FDA) has approved Trulicity (dulaglutide; Eli Lilly) pen as adjunct to diet and exercise to improve glycemic control in in adults with type 2 diabetes. Dulaglutide, a ...

Trulicity Pen Now Available for Type 2 Diabetes Eli Lilly announced the launch of Trulicity (dulaglutide) pen indicated as adjunct to diet and exercise to ipmrove glycemic control in adults with type ...

Eli Lilly has launched its once-weekly diabetes therapy Trulicity in the US, hoping to break into the fast growing, competitive GLP-1 agonist market. Trulicity (dulaglutide) was approved by the FDA at ...

TORONTO, Feb. 16, 2016 /CNW/ - Eli Lilly Canada announced the approval of Trulicity™ (dulaglutide), a once-weekly glucagon-like peptide-1 (GLP-1) receptor agonist indicated for the treatment of adults ...

-- If approved, Lilly's GLP-1 receptor agonistwill provide type 2 diabetes patients a once-weekly treatment option in a single-dose, ready-to-use pen INDIANAPOLIS, Sept. 26, 2014 /PRNewswire/ -- The ...